AnnualMeeting2016
Binimetinib combined with Encorafenib advantages or disadvantages over BRAF-MEK inhibitor
578 0 Acute Lymphoblastic Leukemia Free
Trending
Autoimmune can be delayed in immunotherapy Fadi Braiteh, MD
Deficient mismatch repair in urothelial cancer
Mutation load and gene profiles appear to have a significant impact on response rates and survival
Smoking does not predispose higher response rate to Atezolizumab from IMvigor 210
PD-L1 expression in tumor and immune cells in the microenvironment from the POPLAR trial
Best way to test newly diagnosed NSCLC in the community setting
Atezolizumab differences in Squamous Cell Carcinomas versus the Non-Squamous Cancers #Annual Meeting16
Percentage of patient with urothelial cancer that are cisplatin ineligible
Are safety and adverse event profile appears similar between early trials in both Anti PD-1 and Anti PD-L1
PALOMA trials summary and Palbociclib in ER-positive breast cancer
Current and future Immunotherapy outlook in breast cancer from Annual Meeting 2016
Predictive and Prognostic biomarkers for Brain Metastasis
My videos
Are safety and adverse event profile appears similar between early trials in both Anti PD-1 and Anti PD-L1
Previous cytotoxin patients thought they were on placebo during atezolizumab trial due to low toxicity side effects
